NYSE:AZN - AstraZeneca Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$39.15 -0.09 (-0.23 %)
(As of 12/16/2018 04:00 PM ET)
Previous Close$39.15
Today's Range$38.91 - $39.21
52-Week Range$32.69 - $41.78
Volume4.63 million shs
Average Volume4.37 million shs
Market Capitalization$99.16 billion
P/E Ratio9.15
Dividend Yield2.25%
Beta0.55
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, Symbicort Turbuhaler, and Tudorza Pressair for respiratory diseases; Fluenz FluMist/Tetra Quadrivalen and Synagis3 for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, and Vimovo4 for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. AstraZeneca PLC has a strategic partnership with Bicycle Therapeutics; and with Biothera Pharmaceuticals, Inc. to evaluate cancer related drugs, as well as has a collaboration agreement with Innate Pharma S.A. for oncology development. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC has clinical collaboration with Immunomedics, Inc. for the development of Imfinzi(R) and sacituzumab govitecan combination therapy, to include second-line metastatic non-small cell lung cancer. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.

Receive AZN News and Ratings via Email

Sign-up to receive the latest news and ratings for AZN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSE
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNYSE:AZN
Previous Symbol
CUSIPN/A
Phone44-20-3749-5000

Debt

Debt-to-Equity Ratio1.36
Current Ratio0.86
Quick Ratio0.66

Price-To-Earnings

Trailing P/E Ratio9.15
Forward P/E Ratio23.30
P/E Growth2.2

Sales & Book Value

Annual Sales$22.47 billion
Price / Sales4.41
Cash Flow$3.3404 per share
Price / Cash Flow11.72
Book Value$6.57 per share
Price / Book5.96

Profitability

EPS (Most Recent Fiscal Year)$4.28
Net Income$3.00 billion
Net Margins11.29%
Return on Equity27.32%
Return on Assets6.46%

Miscellaneous

Employees61,100
Outstanding Shares2,532,900,000
Market Cap$99.16 billion
OptionableOptionable

AstraZeneca (NYSE:AZN) Frequently Asked Questions

What is AstraZeneca's stock symbol?

AstraZeneca trades on the New York Stock Exchange (NYSE) under the ticker symbol "AZN."

How often does AstraZeneca pay dividends? What is the dividend yield for AstraZeneca?

AstraZeneca declared a semiannual dividend on Friday, July 27th. Stockholders of record on Friday, August 10th will be paid a dividend of $0.45 per share on Monday, September 10th. This represents a dividend yield of 2.35%. The ex-dividend date is Thursday, August 9th. View AstraZeneca's Dividend History.

When did AstraZeneca's stock split? How did AstraZeneca's stock split work?

Shares of AstraZeneca split on Monday, July 27th 2015. The 2-1 split was announced on Friday, June 26th 2015. The newly issued shares were issued to shareholders after the closing bell on Friday, July 24th 2015. An investor that had 100 shares of AstraZeneca stock prior to the split would have 200 shares after the split.

How were AstraZeneca's earnings last quarter?

AstraZeneca plc (NYSE:AZN) released its earnings results on Thursday, November, 8th. The company reported $0.71 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.33 by $0.38. The company had revenue of $5.34 billion for the quarter, compared to analyst estimates of $5.26 billion. AstraZeneca had a net margin of 11.29% and a return on equity of 27.32%. The company's revenue was down 14.3% compared to the same quarter last year. During the same quarter last year, the company posted $1.12 earnings per share. View AstraZeneca's Earnings History.

When is AstraZeneca's next earnings date?

AstraZeneca is scheduled to release their next quarterly earnings announcement on Friday, February 1st 2019. View Earnings Estimates for AstraZeneca.

What guidance has AstraZeneca issued on next quarter's earnings?

AstraZeneca issued an update on its FY18 earnings guidance on Thursday, November, 8th. The company provided earnings per share (EPS) guidance of $3.30-3.50 for the period, compared to the Thomson Reuters consensus estimate of $3.34. The company issued revenue guidance of low single-digit percentage increase, compared to the consensus revenue estimate of $22.13 billion.AstraZeneca also updated its FY 2018 guidance to $3.30-3.50 EPS.

What price target have analysts set for AZN?

16 analysts have issued twelve-month target prices for AstraZeneca's stock. Their forecasts range from $38.00 to $48.00. On average, they expect AstraZeneca's stock price to reach $43.60 in the next twelve months. This suggests a possible upside of 11.4% from the stock's current price. View Analyst Price Targets for AstraZeneca.

What is the consensus analysts' recommendation for AstraZeneca?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AstraZeneca in the last year. There are currently 2 sell ratings, 5 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for AstraZeneca.

Has AstraZeneca been receiving favorable news coverage?

Media headlines about AZN stock have trended somewhat positive on Sunday, according to InfoTrie. InfoTrie ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. AstraZeneca earned a news impact score of 1.0 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 4.0 out of 10, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near term.

Who are some of AstraZeneca's key competitors?

Who are AstraZeneca's key executives?

AstraZeneca's management team includes the folowing people:
  • Mr. Pascal Soriot, CEO & Exec. Director (Age 59)
  • Mr. Marc Dunoyer, Exec. Director & CFO (Age 66)
  • Ms. Pam P. Cheng, Exec. Vice-Pres of Operations & Information Technology (Age 47)
  • Mr. Jefrey Pott, Gen. Counsel
  • Ms. Katarina Ageborg, Exec. VP of Sustainability & Chief Compliance Officer

Who are AstraZeneca's major shareholders?

AstraZeneca's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Primecap Management Co. CA (2.19%), Dodge & Cox (2.02%), Jennison Associates LLC (1.57%), FMR LLC (1.39%), Fisher Asset Management LLC (0.53%) and Capital International Investors (0.39%). View Institutional Ownership Trends for AstraZeneca.

Which major investors are selling AstraZeneca stock?

AZN stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Dodge & Cox, Cullen Capital Management LLC, Federated Investors Inc. PA, Renaissance Technologies LLC, Sector Gamma AS, Epoch Investment Partners Inc. and York Capital Management Global Advisors LLC. View Insider Buying and Selling for AstraZeneca.

Which major investors are buying AstraZeneca stock?

AZN stock was bought by a variety of institutional investors in the last quarter, including Jennison Associates LLC, FMR LLC, Primecap Management Co. CA, Franklin Resources Inc., Bank of Montreal Can, Russell Investments Group Ltd., Fisher Asset Management LLC and Neuberger Berman Group LLC. View Insider Buying and Selling for AstraZeneca.

How do I buy shares of AstraZeneca?

Shares of AZN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AstraZeneca's stock price today?

One share of AZN stock can currently be purchased for approximately $39.15.

How big of a company is AstraZeneca?

AstraZeneca has a market capitalization of $99.16 billion and generates $22.47 billion in revenue each year. The company earns $3.00 billion in net income (profit) each year or $4.28 on an earnings per share basis. AstraZeneca employs 61,100 workers across the globe.

What is AstraZeneca's official website?

The official website for AstraZeneca is http://www.astrazeneca.com.

How can I contact AstraZeneca?

AstraZeneca's mailing address is 1 FRANCIS CRICK AVENUE CAMBRIDGE BIOMEDICAL CAMPUS, CAMBRIDGE X0, CB2 0AA. The company can be reached via phone at 44-20-3749-5000 or via email at [email protected]


MarketBeat Community Rating for AstraZeneca (NYSE AZN)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  665 (Vote Outperform)
Underperform Votes:  989 (Vote Underperform)
Total Votes:  1,654
MarketBeat's community ratings are surveys of what our community members think about AstraZeneca and other stocks. Vote "Outperform" if you believe AZN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AZN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel